A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva

Next Previous
Trial Profile

A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs VGX 3100 (Primary) ; Imiquimod
  • Indications Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • Focus Therapeutic Use
  • Sponsors Inovio Pharmaceuticals

    • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 1 Aug 2020 to 1 Sep 2021.
    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 27 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top